These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
391 related articles for article (PubMed ID: 16207309)
1. The effects of inhibiting cytochrome P450 3A, p-glycoprotein, and gastric acid secretion on the oral bioavailability of methadone in dogs. Kukanich B; Lascelles BD; Aman AM; Mealey KL; Papich MG J Vet Pharmacol Ther; 2005 Oct; 28(5):461-6. PubMed ID: 16207309 [TBL] [Abstract][Full Text] [Related]
2. Effects of ketoconazole on the intestinal metabolism, transport and oral bioavailability of K02, a novel vinylsulfone peptidomimetic cysteine protease inhibitor and a P450 3A, P-glycoprotein dual substrate, in male Sprague-Dawley rats. Zhang Y; Hsieh Y; Izumi T; Lin ET; Benet LZ J Pharmacol Exp Ther; 1998 Oct; 287(1):246-52. PubMed ID: 9765344 [TBL] [Abstract][Full Text] [Related]
3. Multiple oral dosing of ketoconazole influences pharmacokinetics of quinidine after intravenous and oral administration in beagle dogs. Kuroha M; Shirai Y; Shimoda M J Vet Pharmacol Ther; 2004 Oct; 27(5):355-9. PubMed ID: 15500574 [TBL] [Abstract][Full Text] [Related]
4. The influence of modulation of P-glycoprotein and /or cytochrome P450 3A on the pharmacokinetics and pharmacodynamics of orally administered morphine in dogs. Gadeyne C; Van der Heyden S; Gasthuys F; Croubels S; Schauvliege S; Polis I J Vet Pharmacol Ther; 2011 Oct; 34(5):417-23. PubMed ID: 21241325 [TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of florfenicol and its metabolite, florfenicol amine, in dogs. Park BK; Lim JH; Kim MS; Hwang YH; Yun HI Res Vet Sci; 2008 Feb; 84(1):85-9. PubMed ID: 17570454 [TBL] [Abstract][Full Text] [Related]
6. Analytical determination and pharmacokinetics of robenacoxib in the dog. Jung M; Lees P; Seewald W; King JN J Vet Pharmacol Ther; 2009 Feb; 32(1):41-8. PubMed ID: 19161454 [TBL] [Abstract][Full Text] [Related]
7. Bioavailability and pharmacokinetics of oral and injectable formulations of methadone after intravenous, oral, and intragastric administration in horses. Linardi RL; Stokes AM; Keowen ML; Barker SA; Hosgood GL; Short CR Am J Vet Res; 2012 Feb; 73(2):290-5. PubMed ID: 22280392 [TBL] [Abstract][Full Text] [Related]
8. Drug-metabolizing enzyme inhibition by ketoconazole does not reduce interindividual variability of CYP3A activity as measured by oral midazolam. Chen M; Nafziger AN; Bertino JS Drug Metab Dispos; 2006 Dec; 34(12):2079-82. PubMed ID: 16997909 [TBL] [Abstract][Full Text] [Related]
9. Plasma profile and pharmacokinetics of dextromethorphan after intravenous and oral administration in healthy dogs. Kukanich B; Papich MG J Vet Pharmacol Ther; 2004 Oct; 27(5):337-41. PubMed ID: 15500572 [TBL] [Abstract][Full Text] [Related]
10. Multiple oral dosing of ketoconazole increases dog exposure to ivermectin. Hugnet C; Lespine A; Alvinerie M J Pharm Pharm Sci; 2007; 10(3):311-8. PubMed ID: 17727794 [TBL] [Abstract][Full Text] [Related]
11. Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. Kharasch ED; Walker A; Hoffer C; Sheffels P Clin Pharmacol Ther; 2004 Nov; 76(5):452-66. PubMed ID: 15536460 [TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of tramadol and the metabolite O-desmethyltramadol in dogs. KuKanich B; Papich MG J Vet Pharmacol Ther; 2004 Aug; 27(4):239-46. PubMed ID: 15305853 [TBL] [Abstract][Full Text] [Related]
13. Voriconazole, but not terbinafine, markedly reduces alfentanil clearance and prolongs its half-life. Saari TI; Laine K; Leino K; Valtonen M; Neuvonen PJ; Olkkola KT Clin Pharmacol Ther; 2006 Nov; 80(5):502-8. PubMed ID: 17112806 [TBL] [Abstract][Full Text] [Related]
14. Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping. Lee JI; Chaves-Gnecco D; Amico JA; Kroboth PD; Wilson JW; Frye RF Clin Pharmacol Ther; 2002 Dec; 72(6):718-28. PubMed ID: 12496753 [TBL] [Abstract][Full Text] [Related]
15. The effect of changes in gastric pH induced by omeprazole on the absorption and respiratory depression of methadone. de Castro J; Aguirre C; Rodríguez-Sasiaín JM; Gómez E; Garrido MJ; Calvo R Biopharm Drug Dispos; 1996 Oct; 17(7):551-63. PubMed ID: 8894114 [TBL] [Abstract][Full Text] [Related]
16. Effects of liver fibrosis on verapamil pharmacokinetics in rats. Chen M; Xu D; Hu XL; Wang H Clin Exp Pharmacol Physiol; 2008 Mar; 35(3):287-94. PubMed ID: 17973928 [TBL] [Abstract][Full Text] [Related]
17. A bioavailability/bioequivalence study of two oral lansoprazole formulations after single administration to healthy volunteers. Jovanović D; Kilibarda V; Maksimović M Pharmazie; 2001 Oct; 56(10):800-2. PubMed ID: 11683127 [TBL] [Abstract][Full Text] [Related]
18. A turnover model of irreversible inhibition of gastric acid secretion by omeprazole in the dog. Abelö A; Eriksson UG; Karlsson MO; Larsson H; Gabrielsson J J Pharmacol Exp Ther; 2000 Nov; 295(2):662-9. PubMed ID: 11046103 [TBL] [Abstract][Full Text] [Related]
19. The effect of short- and long-term administration of verapamil on the disposition of cytochrome P450 3A and P-glycoprotein substrates. Lemma GL; Wang Z; Hamman MA; Zaheer NA; Gorski JC; Hall SD Clin Pharmacol Ther; 2006 Mar; 79(3):218-30. PubMed ID: 16513446 [TBL] [Abstract][Full Text] [Related]
20. Development of an in vivo preclinical screen model to estimate absorption and first-pass hepatic extraction of xenobiotics. II. Use of ketoconazole to identify P-glycoprotein/CYP3A-limited bioavailability in the monkey. Ward KW; Stelman GJ; Morgan JA; Zeigler KS; Azzarano LM; Kehler JR; McSurdy-Freed JE; Proksch JW; Smith BR Drug Metab Dispos; 2004 Feb; 32(2):172-7. PubMed ID: 14744938 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]